RTW Venture Fund (RTW) made two investment announcements yesterday afternoon (9 March) – it participated in the $114m financing round held by Ventyx Biosciences as well as the $36m round held by Visus Therapeutics.
The investments are in companies involved in molecule therapeutics and presbyopia-correcting eye drops
RTW describes the companies as follows:
“Ventyx is a privately-held clinical-stage biotechnology company advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases. Ventyx’s pipeline programs include: (1) a selective allosteric TYK2 inhibitor for a broad range of immunological disorders, (2) a tissue selective S1P1R modulator for inflammatory bowel disease (IBD), and (3) a preclinical NLRP3 inhibitor program.”
“Visus is a privately held clinical-stage pharmaceutical company developing presbyopia-correcting eye drops. Visus plans to use the proceeds from the financing round to advance the clinical development program for its lead asset, BRIMOCHOL™, an investigational drug designed to be a once-daily eye drop correcting for the loss of near vision associated with presbyopia.”
RTW: RTW Venture participates in $114m and $36m financing rounds held by Ventyx Biosciences and Visus Therapeutics